SG11202110986YA - Method for purifying fc region-modified antibody - Google Patents

Method for purifying fc region-modified antibody

Info

Publication number
SG11202110986YA
SG11202110986YA SG11202110986YA SG11202110986YA SG11202110986YA SG 11202110986Y A SG11202110986Y A SG 11202110986YA SG 11202110986Y A SG11202110986Y A SG 11202110986YA SG 11202110986Y A SG11202110986Y A SG 11202110986YA SG 11202110986Y A SG11202110986Y A SG 11202110986YA
Authority
SG
Singapore
Prior art keywords
purifying
region
modified antibody
antibody
modified
Prior art date
Application number
SG11202110986YA
Inventor
Tetsuya Wakabayashi
Yuichiro Shimizu
Masahiro Fukunaga
Eiji Majima
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of SG11202110986YA publication Critical patent/SG11202110986YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
SG11202110986YA 2019-04-10 2020-04-09 Method for purifying fc region-modified antibody SG11202110986YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019074738 2019-04-10
PCT/JP2020/015904 WO2020209318A1 (en) 2019-04-10 2020-04-09 Method for purifying fc region-modified antibody

Publications (1)

Publication Number Publication Date
SG11202110986YA true SG11202110986YA (en) 2021-11-29

Family

ID=72752051

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202110986YA SG11202110986YA (en) 2019-04-10 2020-04-09 Method for purifying fc region-modified antibody

Country Status (13)

Country Link
US (1) US20220213140A1 (en)
EP (1) EP3954696A4 (en)
JP (1) JPWO2020209318A1 (en)
KR (1) KR20210149779A (en)
CN (1) CN113906042A (en)
AU (1) AU2020273072A1 (en)
BR (1) BR112021020204A2 (en)
CA (1) CA3136398A1 (en)
IL (1) IL286982A (en)
MX (1) MX2021012251A (en)
SG (1) SG11202110986YA (en)
TW (1) TW202104244A (en)
WO (1) WO2020209318A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107488228A (en) 2008-04-11 2017-12-19 中外制药株式会社 The antigen binding molecules combined repeatedly with the antigen of multiple molecules
RU2658504C9 (en) 2010-11-30 2018-08-21 Чугаи Сейяку Кабусики Кайся Antigen-binding molecule, that is capable of multiple binding with a lot of antigenic molecules
EP3240804A4 (en) 2014-12-19 2019-01-09 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
KR20230079499A (en) 2016-08-05 2023-06-07 추가이 세이야쿠 가부시키가이샤 Composition for prophylaxis or treatment of il-8 related diseases

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
GB9022547D0 (en) 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
RU2139351C1 (en) 1991-04-25 1999-10-10 Чугаи Сейяку Кабусики Кайся H- and l-chains of monoclonal antibody pm-1 (monat) to human il-6r receptor and their v-region, modified monat, its h- and l-chains and their v-regions, cdr-sequence, dna-sequence
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
PT1024191E (en) 1991-12-02 2008-12-22 Medical Res Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
EP0656941B1 (en) 1992-03-24 2005-06-01 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JPH07509137A (en) 1992-07-24 1995-10-12 セル　ジェネシス，インク． Production of xenoantibodies
EP0754225A4 (en) 1993-04-26 2001-01-31 Genpharm Int Transgenic non-human animals capable of producing heterologous antibodies
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
AU690171B2 (en) 1993-12-03 1998-04-23 Medical Research Council Recombinant binding proteins and peptides
US5994524A (en) 1994-07-13 1999-11-30 Chugai Seiyaku Kabushiki Kaisha Polynucleotides which encode reshaped IL-8-specific antibodies and methods to produce the same
ATE390933T1 (en) 1995-04-27 2008-04-15 Amgen Fremont Inc HUMAN ANTIBODIES AGAINST IL-8 DERIVED FROM IMMUNIZED XENOMICES
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc Human antibodies derived from immunized xenomice
WO2006019447A1 (en) 2004-07-15 2006-02-23 Xencor, Inc. Optimized fc variants
EP2845865A1 (en) 2004-11-12 2015-03-11 Xencor Inc. Fc variants with altered binding to FcRn
CA2594356C (en) 2005-01-05 2018-07-17 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
JP4179517B2 (en) * 2006-02-21 2008-11-12 プロテノバ株式会社 Immunoglobulin affinity ligand
EP1992692B1 (en) * 2006-02-21 2013-01-09 Protenova Co., Ltd. Immunoglobulin affinity ligand
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
MY163473A (en) 2007-09-26 2017-09-15 Chugai Pharmaceutical Co Ltd Modified antibody constant region
HUE024903T2 (en) 2007-12-26 2016-02-29 Xencor Inc Fc variants with altered binding to fcrn
CN107488228A (en) 2008-04-11 2017-12-19 中外制药株式会社 The antigen binding molecules combined repeatedly with the antigen of multiple molecules
JP5229888B2 (en) * 2008-09-30 2013-07-03 独立行政法人産業技術総合研究所 Protein A mutant protein and antibody capture agent with improved easy dissociation in weakly acidic region
TWI667257B (en) 2010-03-30 2019-08-01 中外製藥股份有限公司 Antibodies with modified affinity to fcrn that promote antigen clearance
WO2012016227A2 (en) 2010-07-29 2012-02-02 Xencor, Inc. Antibodies with modified isoelectric points
RU2658504C9 (en) 2010-11-30 2018-08-21 Чугаи Сейяку Кабусики Кайся Antigen-binding molecule, that is capable of multiple binding with a lot of antigenic molecules
WO2012132067A1 (en) 2011-03-30 2012-10-04 中外製薬株式会社 Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
JPWO2012133349A1 (en) * 2011-03-25 2014-07-28 株式会社カネカ Protein for affinity separation matrix
TW201817745A (en) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
TW201726745A (en) 2011-09-30 2017-08-01 中外製藥股份有限公司 Antigen-binding molecule for promoting loss of antigens
EP3892638A1 (en) 2012-05-30 2021-10-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for eliminating aggregated antigens
CN107964042B (en) 2012-05-30 2022-04-19 中外制药株式会社 Target tissue specific antigen binding molecules
EP2970508A4 (en) 2013-03-15 2016-12-14 Permeon Biologics Inc Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
JP6153801B2 (en) 2013-07-23 2017-06-28 旭化成ホームズ株式会社 nozzle
EP3042912A4 (en) * 2013-09-04 2017-05-03 Protenova Co., Ltd. Immunoglobulin-binding domain multimer
JP2015185254A (en) 2014-03-20 2015-10-22 日立マクセル株式会社 Nonaqueous electrolyte secondary battery
EP3240804A4 (en) * 2014-12-19 2019-01-09 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
TW202231662A (en) * 2015-12-18 2022-08-16 日商中外製藥股份有限公司 Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use

Also Published As

Publication number Publication date
IL286982A (en) 2021-12-01
AU2020273072A1 (en) 2021-12-09
US20220213140A1 (en) 2022-07-07
CA3136398A1 (en) 2020-10-15
TW202104244A (en) 2021-02-01
EP3954696A4 (en) 2023-07-26
KR20210149779A (en) 2021-12-09
EP3954696A1 (en) 2022-02-16
MX2021012251A (en) 2021-11-12
BR112021020204A2 (en) 2021-12-07
WO2020209318A1 (en) 2020-10-15
CN113906042A (en) 2022-01-07
JPWO2020209318A1 (en) 2020-10-15

Similar Documents

Publication Publication Date Title
IL286982A (en) Method for purifying fc region-modified antibody
EP3306310A4 (en) Method for quantifying monoclonal antibody
EP3294766C0 (en) Humanized antibody or fragment thereof specific for cd3
IL281570A (en) Methods for purifying heterodimeric, multispecific antibodies
EP3845548A4 (en) Method for purifying antibody or antibody-like molecule
IL265016B (en) Methods for purifying antibodies
EP3118210A4 (en) Method for purifying immunoglobulin
EP3805246A4 (en) Method for purifying long chain polypeptide
IL280140A (en) Antigen purification method
EP3521299A4 (en) Method for purifying recombinant protein
IL282035A (en) Method for purifying cannabinoids
IL272807A (en) Method for purifying proteins
EP3904320A4 (en) Method for purifying hexafluorobutadiene
EP3291837A4 (en) Monoclonal antibody cocktails for treatment of ebola infections
EP3092002A4 (en) Method of purifying monoclonal antibodies
EP3375875A4 (en) SEPARATING AGENT FOR HUMAN SERUM-DERIVED IgG POLYCLONAL ANTIBODIES, AND METHOD FOR SEPARATING HUMAN SERUM-DERIVED IgG POLYCLONAL ANTIBODIES USING SAME
IL289959A (en) Methods for purifying antibodies
EP3738681A4 (en) Manufacturing method for exhaust gas purification device
IL277056A (en) Methods for purifying antibodies
GB201806736D0 (en) Method for virus purification
EP3560571C0 (en) Method for purifying fructose
GB201911685D0 (en) Process for purifying monoclonal antibodies
EP4019930A4 (en) Purification method for oils
EP3336172A4 (en) Method for producing antigen specific monoclonal antibody
PT3359189T (en) Humanized anti psa (5a10) antibodies